Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026Advanced Pharmaceutical BulletinOpen Access

Translational Landscape of Nanopharmaceuticals: Progress and Prospects on Biomacromolecule Delivery and Active Targeting

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAzam SafaryMAMostafa Akbarzadeh-Khiavi

Discussion

Loading...

Member takes

Overview

Randomized trial examines delivery efficacy of nanopharmaceuticals in clinical settings, suggesting design improvements for better outcomes.

Key Points

  • This research investigates the gaps between laboratory advancements and clinical applications of nanopharmaceuticals.
  • Examined enzyme-conjugated nanoparticles and EGFR-targeted gold nanoparticles
  • Analyzed regulatory hurdles and biological factors impacting clinical translation
  • Prioritized manufacturability and robustness in design principles
  • Identified that protein corona formation limits targeting specificity.
  • Noted manufacturing challenges increase production costs and affect scalability.
  • Highlighted the need for designs that address regulatory practicality to enhance clinical viability.

Cite This Study

Safary et al. (2026) studied this question.

synapsesocial.com/papers/6a362f63db0793dc1a536d7fhttps://doi.org/10.34172/apb.47355
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Engineering strategies and translational progress in targeted nanoparticle drug delivery2026
  2. 2The Translational Paradox of Cancer Nanomedicine: Biological, Pharmacokinetic, and Manufacturing Barriers to Clinical Success2026
  3. 3Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality2026
  4. 4Nanoparticles for Drug Delivery: Design, Mechanisms, and Clinical Translation2026
  5. 5The Reality of Active Targeting in Nanomedicine: Promise Versus Performance2026